These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 17391433)

  • 81. Site-specific N-glycosylation analysis of soluble Fcγ receptor IIIb in human serum.
    Yagi H; Takakura D; Roumenina LT; Fridman WH; Sautès-Fridman C; Kawasaki N; Kato K
    Sci Rep; 2018 Feb; 8(1):2719. PubMed ID: 29426894
    [TBL] [Abstract][Full Text] [Related]  

  • 82. N-glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and Fc fusion proteins.
    Higel F; Seidl A; Sörgel F; Friess W
    Eur J Pharm Biopharm; 2016 Mar; 100():94-100. PubMed ID: 26775146
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Producing Biologics with Defined N-Glycosylation in Plants.
    Esqueda A; Chen Q
    Methods Mol Biol; 2023; 2597():235-250. PubMed ID: 36374425
    [TBL] [Abstract][Full Text] [Related]  

  • 84. A control strategy to investigate the relationship between specific productivity and high-mannose glycoforms in CHO cells.
    Zalai D; Hevér H; Lovász K; Molnár D; Wechselberger P; Hofer A; Párta L; Putics Á; Herwig C
    Appl Microbiol Biotechnol; 2016 Aug; 100(16):7011-24. PubMed ID: 26910040
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins.
    Beck A; Wagner-Rousset E; Bussat MC; Lokteff M; Klinguer-Hamour C; Haeuw JF; Goetsch L; Wurch T; Van Dorsselaer A; Corvaïa N
    Curr Pharm Biotechnol; 2008 Dec; 9(6):482-501. PubMed ID: 19075687
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Principles of
    Boune S; Hu P; Epstein AL; Khawli LA
    Antibodies (Basel); 2020 Jun; 9(2):. PubMed ID: 32532067
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Glycoforms of Immunoglobulin G Based Biopharmaceuticals Are Differentially Cleaved by Trypsin Due to the Glycoform Influence on Higher-Order Structure.
    Falck D; Jansen BC; Plomp R; Reusch D; Haberger M; Wuhrer M
    J Proteome Res; 2015 Sep; 14(9):4019-28. PubMed ID: 26244886
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Novel long-lasting interferon alpha derivatives designed by glycoengineering.
    Ceaglio N; Etcheverrigaray M; Kratje R; Oggero M
    Biochimie; 2008 Mar; 90(3):437-49. PubMed ID: 18039474
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Evaluation of a glycoengineered monoclonal antibody via LC-MS analysis in combination with multiple enzymatic digestion.
    Liu R; Giddens J; McClung CM; Magnelli PE; Wang LX; Guthrie EP
    MAbs; 2016; 8(2):340-6. PubMed ID: 26514686
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Coupling CRISPR interference with FACS enrichment: New approach in glycoengineering of CHO cell lines for therapeutic glycoprotein production.
    Glinšek K; Kramer L; Krajnc A; Kranjc E; Pirher N; Marušič J; Hellmann L; Podobnik B; Štrukelj B; Ausländer D; Gaber R
    Biotechnol J; 2022 Jul; 17(7):e2100499. PubMed ID: 35481906
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Implementation of Glycan Remodeling to Plant-Made Therapeutic Antibodies.
    Bennett LD; Yang Q; Berquist BR; Giddens JP; Ren Z; Kommineni V; Murray RP; White EL; Holtz BR; Wang LX; Marcel S
    Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29385073
    [No Abstract]   [Full Text] [Related]  

  • 92. Glycosylation of Recombinant Anticancer Therapeutics in Different Expression Systems with Emerging Technologies.
    Nadeem T; Khan MA; Ijaz B; Ahmed N; Rahman ZU; Latif MS; Ali Q; Rana MA
    Cancer Res; 2018 Jun; 78(11):2787-2798. PubMed ID: 29789420
    [TBL] [Abstract][Full Text] [Related]  

  • 93. The Mechanistic Impact of N-Glycosylation on Stability, Pharmacokinetics, and Immunogenicity of Therapeutic Proteins.
    Zhou Q; Qiu H
    J Pharm Sci; 2019 Apr; 108(4):1366-1377. PubMed ID: 30471292
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Controlling the time evolution of mAb N-linked glycosylation, Part I: Microbioreactor experiments.
    Villiger TK; Roulet A; Périlleux A; Stettler M; Broly H; Morbidelli M; Soos M
    Biotechnol Prog; 2016 Sep; 32(5):1123-1134. PubMed ID: 27254475
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Rational design of glycoengineered interferon-β analogs with improved aggregation state: experimental validation.
    Samoudi M; Minuchehr Z; Harcum SW; Tabandeh F; Omid Yeganeh N; Khodabandeh M
    Protein Eng Des Sel; 2017 Jan; 30(1):23-30. PubMed ID: 27881683
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Insights into the Impact of Heterogeneous Glycosylation on the Pharmacokinetic Behavior of Follistatin-Fc-Based Biotherapeutics.
    Datta-Mannan A; Huang L; Pereira J; Yaden B; Korytko A; Croy JE
    Drug Metab Dispos; 2015 Dec; 43(12):1882-90. PubMed ID: 26354950
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Strategies to Develop Therapeutic N- and O-Hyperglycosylated Proteins.
    Gugliotta A; Ceaglio N; Etcheverrigaray M; Kratje R; Oggero M
    Methods Mol Biol; 2018; 1674():163-181. PubMed ID: 28921436
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Comprehensive manipulation of glycosylation profiles across development scales.
    Loebrich S; Clark E; Ladd K; Takahashi S; Brousseau A; Kitchener S; Herbst R; Ryll T
    MAbs; 2019; 11(2):335-349. PubMed ID: 30252592
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Mammalian cell-produced therapeutic proteins: heterogeneity derived from protein degradation.
    Dorai H; Ganguly S
    Curr Opin Biotechnol; 2014 Dec; 30():198-204. PubMed ID: 25118137
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Glycosylation of Therapeutic Proteins: A Critical Quality Attribute.
    Delobel A
    Methods Mol Biol; 2021; 2271():1-21. PubMed ID: 33907996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.